Products The fixed combination Xultophy was approved in many countries and in the EU in 2014 as an injection solution in a prefilled pen. It was released in the United States in 2016. Structure and properties IDegLira is the name given to the combination of the insulin insulin degludec (IDeg, Tresiba) with the GLP-1 receptor … IDegLira
Products Sitagliptin is commercially available in film-coated tablet form as a monopreparation (Januvia) and as a fixed combination with metformin (Janumet, Janumet XR). It was approved in many countries in 2007 as the first representative of the gliptins. The combination with simvastatin is not yet registered in many countries (Juvisync). Generics were approved in 2018. … Sitagliptin
Effects Alpha-glucosidase inhibitors (ATC A10BF) have antidiabetic properties: Glucose is released more slowly in the gut and absorbed more slowly into the blood Decrease the rise in blood glucose after meals and blood sugar fluctuations. Do not cause hypoglycemia as monotherapy Mechanism of action The action is based on the inhibition of intestinal enzymes (alpha-glucosidases) … Alpha-Glucosidase Inhibitors
Products In 2012, dapagliflozin (Forxiga) was approved in the EU as the first agent in the new group of SGLT2 inhibitors. Several drugs are now on the market worldwide (see below). Structure and properties The SGLT2 inhibitors are derived from phlorizin, a -glucoside and natural substance first isolated from apple tree bark in 1835. Phlorizin … SGLT2 Inhibitor
Products Buformin (Silubin retard, dragées) is no longer commercially available in many countries and many more because of the potential adverse effects. Structure and properties Buformin (C6H15N5, Mr = 157.2 g/mol) is a 1-butylbiguanide with a similar structure to metformin from the same drug group. It is present in drugs as buformin hydrochloride. Effects Buformin … Buformin
